Citius Oncology, Inc. (CTOR) Stock Price & Analysis
Citius Oncology, Inc. (CTOR) closed at USD 0.75 on Thursday, October 15, 2026, down 1.43% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.76; the Oct 15, 2026 session ranged USD 0.75–0.77 on volume of 10,995 shares. Market capitalization is $78.90M, with a 52-week range of USD 0.49–2.25 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CTOR.md
Key facts (CTOR)
- Analysts: Strong Buy (mean 1.00 on a 1–5 scale) (1 analysts), mean target USD 4 (range 4–4).
- Total return with dividends: 1Y -58.3% vs S&P 500 +18.1%; 5Y -92.6% vs S&P 500 +85.1%.
Analysts (CTOR)
Consensus Strong Buy (mean 1.00 on a 1–5 scale), 1 analysts; mean target USD 4 (low 4, high 4).
Total return (dividends reinvested) (CTOR)
| 1Y (from 2025-10-16) | 5Y (from 2022-12-05) | |
|---|---|---|
| Total return | -58.3% | -92.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -58.5% | -49.1% |
| Volatility (annualized) | 91.3% | 190.2% |
| Max drawdown | -72.5% (Oct 2025→Mar 2026) | -98.7% (Aug 2024→Mar 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 0.75 |
|---|---|
| Change | ▼ 1.43% (down) |
| Previous Close | USD 0.76 |
| Open | USD 0.76 |
| Day Range | USD 0.75 – 0.77 |
| 52-Week Range | USD 0.49 – 2.25 |
| Volume | 10,995 shares |
| Market Cap | $78.90M |
| Exchange | NCM |
Technical Analysis (CTOR)
Nexqual's technical model rates CTOR "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.38 (neutral) |
| vs SMA50 | Below (USD 0.87) |
| MACD | -0.03 (negative) |
Analyst Ratings (CTOR)
Wall Street analysts rate CTOR "Strong Buy" based on 1 analysts, with a mean price target of USD 4 (range USD 4–4), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 4 |
| High Target | USD 4 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CTOR)
| Revenue Estimate | $5.77M |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.08 vs est -0.07 ▼ miss |
| 2026-03-31 | USD -0.27 vs est -0.01 ▼ miss |
| 2025-12-31 | USD -0.06 vs est -0.04 ▼ miss |
| 2025-09-30 | USD -0.06 vs est -0.06 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (CTOR)
| Total Revenue | $7.11M |
|---|---|
| Gross Margin | +74.82% |
| Operating Margin | -595.55% |
| Profit Margin | +0.00% |
| ROE | -126.58% |
| Debt / Equity | 0.25 |
| Current Ratio | 0.73 |
| Total Cash | $16.56M |
| Total Debt | $10.21M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (CTOR)
Nexqual rates Citius Oncology, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $17M cash vs $10M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$5M (FY ended Sep 2025, 10-K) |
| Efficiency | Critical — ROE -127%, ROA -29.1% |
Ownership (CTOR)
| Insider Ownership | +77.51% |
|---|---|
| Institutional Ownership | +15.21% |
| Shares Outstanding | 105.76M |
| Float | 30.98M |
| Short % of Float | +0.98% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (CTOR)
Citius Oncology, Inc. is led by Leonard L. Mazur (age 80), CEO, President & Executive Chairman, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO, President & Executive Chairman | Leonard L. Mazur (age 80) |
|---|---|
| Secretary & Executive Vice Chairman | Myron Z. Holubiak (age 78) |
| CFO & Treasurer | Jaime Bartushak (age 57) |
Major Backers & Investors (CTOR)
Notable institutional backers of Citius Oncology, Inc. include Armistice Capital, LLC, Bank of America Corporation, UBS Group AG, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 9.36% |
| Bank of America Corporation | 4.12% |
| UBS Group AG | 0.36% |
| Fidelity | 0.22% |
| IFP Advisors, Inc | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.31% |
| Geode Capital | 0.26% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.31 | ▲ 7.13% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt